



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



THZ2

Item No. 31055

CAS Registry No.: 1604810-84-5
Formal Name: N-[3-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-3-[[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-benzamide
MF: C₃₁H₂₈ClN₇O₂
FW: 566.1
Purity: ≥98%
UV/Vis.: λ_{max}: 214, 278 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

THZ2 is supplied as a solid. A stock solution may be made by dissolving the THZ2 in the solvent of choice, which should be purged with an inert gas. THZ2 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of THZ2 in these solvents is approximately 30 mg/ml.

THZ2 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, THZ2 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. THZ2 has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

THZ2 is a Cdk7 inhibitor (IC₅₀ = 13.9 nM) and a derivative of THZ1 (Item No. 9002215).¹ It is selective for Cdk7 over Cdk1, -2, -5, -8, and -9 (IC₅₀s = 96.9, 222, 134, 6,830, and 194 nM, respectively). THZ2 (0.001-1 nM) reduces proliferation of BT-549, HCC70, and MDA-MB-468 triple-negative breast cancer (TNBC) cells. *In vivo*, THZ2 (10 mg/kg) reduces tumor volume in an MDA-MB-231 mouse xenograft model. It also reduces tumor weight and volume, as well as the number of lung metastases, in an SJSA-1 osteosarcoma orthotopic mouse xenograft model.²

References

1. Wang, Y., Zhang, T., Kwiatkowski, N., *et al.* CDK7-dependent transcriptional addiction in triple-negative breast cancer. *Cell* **163**(1), 174-186 (2015).
2. Zhang, J., Liu, W., Zou, C., *et al.* Targeting super-enhancer-associated oncogenes in osteosarcoma with THZ2, a covalent CDK7 inhibitor. *Clin. Cancer Res.* **26**(11), 2681-2692 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM